Daily Roundup

SEQ.ASX HUM.ASX 1AD.ASX MEM.ASX CUV.ASX

Sequoia Financial Group Requests Trading Halt, Pending Divestment Announcement

Sequoia Financial Group Ltd (ASX: SEQ) has requested an immediate trading halt on its shares, pending the release of an announcement regarding the divestment of a subsidiary. The trading halt will remain in place until the earlier of the announcement being made public or the market opening on March 23.

The company has not specified the reasons behind the planned divestment, but has stated that it is a material transaction. Investors and analysts will be keen to learn more details once the announcement is made.

This follows Sequoia's earlier announcement of a temporary pause in trading of its securities, the reasons for which were not disclosed. The latest trading halt suggests the company is preparing to share significant news with the market.

Takeovers Panel Receives Review Application for Humm Group

In other news, the Takeovers Panel has received an application from Mr. Andrew Abercrombie seeking a review of the Panel's previous decision to make a declaration of unacceptable circumstances in Humm Group Limited (ASX: HUM).

A review panel has not yet been appointed, and no decision has been made on whether to conduct further proceedings. The Panel has not commented on the merits of the application.

This latest development adds another twist to the ongoing situation surrounding Humm Group, which has been the subject of regulatory scrutiny in recent months.

AdAlta Secures New Patent in Canada for Lead Candidate AD-214

Shifting gears, biotech company AdAlta Limited (ASX: 1AD) has announced that it has been granted a new composition of matter patent for its lead product AD-214 in Canada. This patent, valid until 2036, completes the global patent protection for AD-214 in major commercial markets.

The new Canadian patent covers the i-body sequence used in AD-214, as well as related pharmaceutical compositions and therapeutic applications, including for idiopathic pulmonary fibrosis and kidney fibrosis. This milestone provides AdAlta with robust intellectual property protection for its first-in-class anti-fibrotic asset.

Memphasys Maintains Middle East Operations, Secures New Orders

Lastly, Memphasys Limited (ASX: MEM) has confirmed that its commercial operations in the Middle East and North Africa (MENA) region remain unaffected by the ongoing geopolitical instability in parts of the region. The company has secured new orders from customers in the United Arab Emirates and Iraq, demonstrating continued regional demand for its Felix™ System.

Memphasys is also making progress in advancing regulatory approvals and commercial entry into Egypt and Turkey, two key strategic markets for the company. The resilience of its business model, focused on direct clinic engagement and recurring cartridge revenue, has allowed Memphasys to navigate the regional challenges.

Looking ahead, the company remains confident in the continued rollout of the Felix™ System across the MENA region and broader international markets.